ECSP088504A - Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos - Google Patents

Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos

Info

Publication number
ECSP088504A
ECSP088504A EC2008008504A ECSP088504A ECSP088504A EC SP088504 A ECSP088504 A EC SP088504A EC 2008008504 A EC2008008504 A EC 2008008504A EC SP088504 A ECSP088504 A EC SP088504A EC SP088504 A ECSP088504 A EC SP088504A
Authority
EC
Ecuador
Prior art keywords
treatment
flibanserine
premenopause
sexual desire
desire disorders
Prior art date
Application number
EC2008008504A
Other languages
English (en)
Inventor
Stephanie Pollentier
Robert Pyke
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807895&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of ECSP088504A publication Critical patent/ECSP088504A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere al uso de flibanserina para la preparación de un medicamento para el tratamiento de trastornos del deseo sexual premenopáusicos
EC2008008504A 2005-11-08 2008-06-05 Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos ECSP088504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73440505P 2005-11-08 2005-11-08
US83101506P 2006-07-14 2006-07-14

Publications (1)

Publication Number Publication Date
ECSP088504A true ECSP088504A (es) 2008-07-30

Family

ID=37807895

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008504A ECSP088504A (es) 2005-11-08 2008-06-05 Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos

Country Status (30)

Country Link
US (4) US20070105869A1 (es)
EP (1) EP1948177B1 (es)
JP (2) JP5386173B2 (es)
KR (2) KR101436793B1 (es)
CN (1) CN103251598A (es)
AR (1) AR059390A1 (es)
AT (1) ATE521352T1 (es)
AU (1) AU2006311038B2 (es)
BR (1) BRPI0618239A8 (es)
CA (1) CA2626797C (es)
CY (1) CY1112067T1 (es)
DK (1) DK1948177T3 (es)
EA (1) EA014189B1 (es)
EC (1) ECSP088504A (es)
ES (1) ES2372421T3 (es)
HR (1) HRP20110697T1 (es)
IL (1) IL191245A0 (es)
MY (1) MY145439A (es)
NO (1) NO20081527L (es)
NZ (1) NZ568822A (es)
PE (1) PE20070800A1 (es)
PL (1) PL1948177T3 (es)
PT (1) PT1948177E (es)
RS (1) RS51961B (es)
SG (1) SG166820A1 (es)
SI (1) SI1948177T1 (es)
TW (1) TWI389689B (es)
UY (1) UY29899A1 (es)
WO (1) WO2007054476A1 (es)
ZA (1) ZA200802542B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007128802A2 (en) * 2006-05-09 2007-11-15 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of post-menopausal sexual desire disorders
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) * 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
JP2010513390A (ja) 2006-12-20 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体
JP5087011B2 (ja) * 2007-01-23 2012-11-28 馨 井上 眼疾患モデル用非ヒト動物
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2017055935A1 (en) * 2015-09-30 2017-04-06 Symed Labs Limited Amorphous co-precipitates of flibanserin
US20170369475A1 (en) * 2016-06-23 2017-12-28 Sandoz Ag Flibanserin Hydrate
US20230038035A1 (en) * 2021-08-09 2023-02-09 Globalwafers Co., Ltd. Ingot jig assembly and ingot edge-polishing machine tool

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
JP2001504851A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
ATE277606T1 (de) * 1997-06-11 2004-10-15 Procter & Gamble Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
JP3724157B2 (ja) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
EP1256343B1 (en) * 2001-05-11 2006-07-05 Jürgen K. Dr. Beck Flibanserin for the treatment of extrapyramidal movement disorders
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
PL210224B1 (pl) * 2001-08-02 2011-12-30 Bidachem Spa Krystaliczna odmiana polimorficzna flibanseryny, sposób jej wytwarzania, jej zastosowanie, oraz kompozycje farmaceutyczne ją zawierające
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
WO2003097058A1 (en) * 2002-05-22 2003-11-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions containing flibanserin polymorph a
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004063864A2 (en) * 2003-01-06 2004-07-29 Laura Berman Method and system for computerized sexual function assessment of female users
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
CA2641917A1 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
JP2009527525A (ja) * 2006-02-20 2009-07-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁治療用のベンゾイミダゾロン誘導体
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
JP2009541443A (ja) * 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
US20090239881A1 (en) * 2006-07-14 2009-09-24 Boehringer Ingelheim International Gmbh Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900264A1 (ru) * 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления

Also Published As

Publication number Publication date
UY29899A1 (es) 2007-06-29
EP1948177A1 (en) 2008-07-30
KR101436793B1 (ko) 2014-09-03
TW200803857A (en) 2008-01-16
PE20070800A1 (es) 2007-08-13
EP1948177B1 (en) 2011-08-24
AU2006311038B2 (en) 2012-09-20
BRPI0618239A2 (pt) 2011-08-23
KR20140003659A (ko) 2014-01-09
IL191245A0 (en) 2009-08-03
US20070105869A1 (en) 2007-05-10
JP5386173B2 (ja) 2014-01-15
PT1948177E (pt) 2011-09-12
EA200801138A1 (ru) 2008-10-30
JP2009514929A (ja) 2009-04-09
NO20081527L (no) 2008-07-31
ZA200802542B (en) 2009-01-28
ATE521352T1 (de) 2011-09-15
AR059390A1 (es) 2008-04-09
TWI389689B (zh) 2013-03-21
SI1948177T1 (sl) 2011-12-30
CA2626797C (en) 2014-01-21
JP2013177412A (ja) 2013-09-09
US20140329827A1 (en) 2014-11-06
CY1112067T1 (el) 2015-11-04
EA014189B1 (ru) 2010-10-29
BRPI0618239A8 (pt) 2018-05-15
CA2626797A1 (en) 2007-05-18
RS51961B (en) 2012-02-29
ES2372421T3 (es) 2012-01-19
US20130225604A1 (en) 2013-08-29
AU2006311038A1 (en) 2007-05-18
DK1948177T3 (da) 2011-11-21
US20150366862A1 (en) 2015-12-24
MY145439A (en) 2012-02-15
CN103251598A (zh) 2013-08-21
HRP20110697T1 (hr) 2011-10-31
NZ568822A (en) 2011-09-30
WO2007054476A1 (en) 2007-05-18
SG166820A1 (en) 2010-12-29
PL1948177T3 (pl) 2012-01-31
KR20080070059A (ko) 2008-07-29

Similar Documents

Publication Publication Date Title
ECSP088504A (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
UY29417A1 (es) Agentes endoparasiticidas
GT200600077A (es) Imidazoles sustituidos con heterociclilamida
SV2010003701A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2008003780A1 (es) Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras.
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
UY31035A1 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
PE20080455A1 (es) Mirtazapina para el tratamiento de dolor neuropatico
UA96278C2 (ru) Применение флибансерина для лечения расстройств полового влечения в предклимактерический период
CL2008002116A1 (es) Composicion farmaceutica compuesta por la combinacion de 25 a 500 mg de lamotrigina y 0.5 a 20 mg de clonazepam; y uso para el control y tratamiento de enfermedades tales como trastornos convulsivos, sindromes epilepticos y enfermedades relacionadas.
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
ES1056732Y (es) Alargador corporal para la reconstruccion del cuerpo vertebral.